Treatment Sequencing Decisions in ALK+ NSCLC

Opinion
Video

This video segment examines therapeutic strategies for managing disease progression on lorlatinib in ALK-positive metastatic NSCLC, including decision-making considerations and scenarios where switching to lorlatinib from another ALK inhibitor may be beneficial.

Video content above is prompted by the following:

  • If this patient were to experience disease progression on lorlatinib, what would be your next therapeutic approach and why?
    • What considerations would guide your decision-making process?
  • If this patient had started on a different ALK inhibitor, when/why might you consider a switch to lorlatinib?
Recent Videos
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
2 experts are featured in this series.
4 experts in this video
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Related Content
Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

Caroline Seymour
October 26th 2025
Article

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E-mutated non–small cell lung cancer.

Frontline Immunotherapy Improves OS vs BRAF/MEK Inhibitors in BRAF+ NSCLC

Russ Conroy
October 20th 2025
Article

Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E–mutated non–small cell lung cancer.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.

Ivonescimab Combo Boosts PFS in Advanced Squamous NSCLC Trial

Kristi Rosa
October 19th 2025
Article

Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.

OptiTROP-Lung04 data show sacituzumab tirumotecan cut the risk of progression or death by 51% in patients with nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.

Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC

Gina Mauro
October 19th 2025
Article

OptiTROP-Lung04 data show sacituzumab tirumotecan cut the risk of progression or death by 51% in patients with nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.